Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-02-20
Target enrollment:
Participant gender:
Summary
Epidermal growth factor receptor Tyrosine kinase inhibitor (EGFR TKI) have been approved to
treat NSCLC harboring EGFR mutation as first-line therapy. However, the acquired resistance
of EGFR-TKI is a common and severe problem.The study explore the superiority of
anti-angiogenesis drugs (Apatinib, endostatin, anlotinib) plus EGFR TKI versus single
EGFR-TKI.